<DOC>
	<DOCNO>NCT01074073</DOCNO>
	<brief_summary>The purpose study evaluate drug-drug interaction effect Lithium Lurasidone HCl .</brief_summary>
	<brief_title>Lithium Drug-Drug Interaction Study With Lurasidone HCl</brief_title>
	<detailed_description>To compare steady state pharmacokinetic profile lurasidone 120 mg QD administer alone vs. steady state pharmacokinetic profile lurasidone 120 mg QD coadministered steady state lithium 600 mg BID .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>1 . Diagnosis schizophrenia , schizoaffective disorder , schizophreniform . 2 . Females participate study : unable childrenOR willing remain abstinent Day 5 90 day discharge ; 3 . Males must willing remain sexually abstinent use effective method birth control ( e.g . condom ) Day 5 90 day discharge . 4 . Able agree remain prior antipsychotic medication duration study . 1 . Presence history ( within last year ) medical surgical condition ( e.g . gastrointestinal disease ) might interfere absorption , metabolism , excretion orally administer lurasidone . 2 . Positive test result within 30 day prior start study : 3 . Participated another clinical trial receive investigational product within 30 day prior drug administration . 4 . Use concomitant medication prolong QT/QTc interval within 14 day prior Day 5 followup 5 . Use monoamine oxidase inhibitor within 21 day prior Day 1 Restabilization . 6 . Received depot neuroleptic unless last injection least 1 treatment cycle Day 5 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Lithium DDI Lurasidone HCl</keyword>
	<keyword>Male/Female , Schizophrenia Patients</keyword>
</DOC>